{
    "pmcid": "PMC4737107",
    "title": "Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics",
    "study_parameters": {
        "summary": {
            "content": "The study aimed to investigate the impact of thiopurine methyltransferase (TPMT) genotype on thiopurine dose intensity, myelosuppression, and treatment outcomes in childhood acute lymphoblastic leukemia (ALL) within the UK ALL97 trial. The researchers analyzed TPMT genotypes, thiopurine dosages, and treatment outcomes, finding that TPMT heterozygotes, particularly those with the TPMT*1/*3A variant, had better event-free survival (EFS) compared to wild-type patients, despite experiencing more frequent cytopenias. The study concluded that thiopurine-induced cytopenias did not negatively affect treatment outcomes, and TPMT*1/*3A heterozygotes had a superior EFS, while TPMT*1/*3C patients had poorer outcomes, potentially due to non-compliance issues.",
            "citations": [
                "EFS differed significantly by *TPMT*TPMT genotype (Fig [2](#bjh13240-fig-0002)2).",
                "*TPMT*1/*3A*TPMT*1/*3A patients (EFS 88%, 95%CI 81\u201394%) fared significantly better than *TPMT*1/*1*TPMT*1 (EFS 80%, 95%CI 78\u201382%) patients (Fig [2](#bjh13240-fig-0002)2).",
                "Within the UK ALL trials, thiopurine\u2010induced cytopenias did not have a detrimental effect on EFS."
            ]
        },
        "study_type": {
            "content": "Clinical trial, cohort, retrospective",
            "citations": [
                "ALL97 [International Standard Randomized Controlled Trial Number (ISRCTN) registration number ISRCTN26727615] was a randomized comparison of dexamethasone versus prednisone and mercaptopurine versus thioguanine in patients aged 1 to 18 years.",
                "The patient cohort has been previously described (Vora *et al*et al, [2006](#bjh13240-bib-0042)2006).",
                "Dose intensity data was available for 818 of the 1334 (61%) children with *TPMT*TPMT genotypes. There was a significant heterogeneity in dose tolerance by genotype (Table [4](#bjh13240-tbl-0004)4)."
            ]
        },
        "participant_info": {
            "content": [
                "**Age:** Participants were aged 1 to 18 years.",
                "**Gender:** The study included both male and female participants, with specific gender-related analyses indicating differences in dose tolerance and myelosuppression.",
                "**Ethnicity:** Of the 1334 patients with TPMT genotype data, 1160 were white, and 174 belonged to other ethnic groups (71 Asian, 44 mixed race, 20 black, 6 Oriental, and 33 unknown or non-Caucasian).",
                "**Pre-existing Conditions:** None of the TPMT*1/*3C patients had CNS disease at diagnosis or Down syndrome; two had T-cell immunophenotype.",
                "**Study Group Breakdown:**",
                "**TPMT*1/*1:** 1206 patients were homozygous wild-type.",
                "**TPMT*1/*3A:** 99 patients were heterozygous for the TPMT*1/*3A variant allele.",
                "**TPMT*1/*3C:** 17 patients were heterozygous for the TPMT*1/*3C variant allele.",
                "**Other TPMT Variants:** 12 patients had other low activity variant alleles or novel alleles."
            ],
            "citations": [
                "ALL97 [International Standard Randomized Controlled Trial Number (ISRCTN) registration number ISRCTN26727615] was a randomized comparison of dexamethasone versus prednisone and mercaptopurine versus thioguanine in patients aged 1 to 18 years.",
                "*TPMT*TPMT genotype was available for 1334 patients (69% of patients entered onto ALL97); 1160 were white and 174 belonged to other ethnic groups (71 Asian (Indian sub\u2010continent), 44 mixed race, 20 black, 6 Oriental and 33 unknown or non\u2010Caucasian).",
                "1206 patients were homozygous wild\u2010type *TPMT*1/*1*TPMT*1/*1 and 128 patients had low activity variant alleles (99 *TPMT*1/*3A*TPMT*1/*3A; 17 *TPMT*1/*3C*TPMT*1/*3C; 4 *TPMT*1/*2*TPMT*1/*2; two children with the rare alleles *TPMT*1/*9*TPMT*1/*9,* TPMT*1/*21* TPMT*1/*21; three children with novel alleles *TPMT*1/*32, TPMT*1/*33, TPMT*1/*34*TPMT*1/*32, TPMT*1/*33, TPMT*1/*34; one compound heterozygote *TPMT*2/*3A*TPMT*2/*3A; one homozygous *TPMT*3A/*3A*TPMT*3A/*3A and one *TPMT*3C/*3C*TPMT*3C/*3C)."
            ]
        },
        "study_design": {
            "content": [
                "**Study Design**: Randomized controlled trial (RCT) within the UK childhood acute lymphoblastic leukaemia (ALL) trial ALL97, with an add-on thiopurine biological study.",
                "**Study Population**: Children aged 1 to 18 years with acute lymphoblastic leukaemia.",
                "**Sample Size**: TPMT genotype data was available for 1334 patients, representing 69% of those entered into the ALL97 trial.",
                "**Chemotherapy Regimen**: Randomized comparison of dexamethasone versus prednisone and mercaptopurine versus thioguanine, with maintenance therapy including daily oral thiopurine, weekly methotrexate, monthly intravenous vincristine, and 5 days of randomized steroid.",
                "**Trial Phases**: ALL97 and ALL97/99, with modifications in November 1999 extending maintenance therapy to 3 years for boys.",
                "**Dose Titration**: Thiopurine dose was titrated to toxicity from a standard protocol dose, with adjustments based on cell counts.",
                "**Exclusion Criteria**: High-risk patients and those who relapsed or died during the first year of chemotherapy were excluded from thiopurine dosage analysis.",
                "**Data Collection**: Weekly drug dosage and monthly or fortnightly cell counts were recorded and collated by the Clinical Trials Service Unit, Oxford.",
                "**Genotyping**: TPMT genotype was determined from blood samples, and thiopurine metabolite concentrations were measured by high-performance liquid chromatography (HPLC)."
            ],
            "citations": [
                "ALL97 [International Standard Randomized Controlled Trial Number (ISRCTN) registration number ISRCTN26727615] was a randomized comparison of dexamethasone versus prednisone and mercaptopurine versus thioguanine in patients aged 1 to 18 years.",
                "*TPMT*TPMT genotype was available for 1334 patients (69% of patients entered onto ALL97); 1160 were white and 174 belonged to other ethnic groups (71 Asian (Indian sub\u2010continent), 44 mixed race, 20 black, 6 Oriental and 33 unknown or non\u2010Caucasian).",
                "During maintenance patients received daily oral randomized thiopurine, weekly methotrexate, monthly intravenous vincristine and 5 days of randomized steroid."
            ]
        },
        "study_results": {
            "content": [
                "**TPMT heterozygotes**: Had significantly more frequent cytopenias and required dose adjustments more often than TPMT wild-type patients.",
                "**Event-free survival (EFS)**: TPMT*1/*3A heterozygotes had a 5-year EFS of 88%, better than TPMT*1/*1 (80%, P = 0.05) and TPMT*1/*3C (53%, P = 0.002).",
                "**Poor compliance**: Associated with worse EFS (P = 0.02); non-compliance may have contributed to poorer outcomes for TPMT*1/*3C patients.",
                "**Escalated doses**: Patients on escalated doses had worse EFS (P = 0.04).",
                "**Thiopurine-induced cytopenias**: Not detrimental to treatment outcome.",
                "**Hazard ratio for TPMT*1/*3C vs. TPMT*1/*3A**: 4.5, 95% CI 1.7\u201311.8, P = 0.003.",
                "**Odds ratio for non-compliance with thioguanine**: 2.58, 95% CI 1.11\u20135.7, P = 0.04; more marked at OR = 3.60, 95% CI 1.34\u20139.69, P = 0.02 for stricter non-compliance definition."
            ],
            "citations": [
                "TPMT heterozygotes had significantly more frequent cytopenias and therefore required dose adjustments below target levels significantly more often than TPMT wild\u2010type patients although the average dose range was similar for both genotypes.",
                "Event\u2010free survival (EFS) for patients heterozygous for the more common TPMT*1/*3A variant allele (n = 99, 5\u2010year EFS 88%) was better than for both wild\u2010type TPMT*1/*1 (n = 1206, EFS 80%, P = 0\u00b705) and TPMT*1/*3C patients (n = 17, EFS 53%, P = 0\u00b7002); outcomes supported by a multivariate Cox regression analysis.",
                "After stratifying for trial, age group, sex, WBC and steroid used, patients accumulating <750 pmol TGNs/8 \u00d7 10^8^8 red cells on thioguanine had worse EFS than compliant patients (odds ratio [OR] = 2\u00b758, 95% CI: 1\u00b711\u20135\u00b77, *P *P = 0\u00b704); the difference was more marked (OR = 3\u00b760, 95% CI: 1\u00b734\u20139\u00b769, *P *P = 0\u00b702) when the definition of non\u2010compliance was restricted to <500 pmol TGNs/8 \u00d7 10^8^8 red cells."
            ]
        },
        "allele_frequency": {
            "content": "The article provides information about the allele frequencies of TPMT variants in the study population. Here is a summary of the allele frequencies for the TPMT variants mentioned in the study:\n\n| TPMT Genotype | Number of Patients | Frequency (%) |\n|---------------|--------------------|---------------|\n| TPMT*1/*1     | 1206               | 90.4%         |\n| TPMT*1/*3A    | 99                 | 7.4%          |\n| TPMT*1/*3C    | 17                 | 1.3%          |\n| TPMT*1/*2     | 4                  | 0.3%          |\n| TPMT*1/*9     | 2                  | 0.15%         |\n| TPMT*1/*21    | 2                  | 0.15%         |\n| TPMT*1/*32    | 1                  | 0.075%        |\n| TPMT*1/*33    | 1                  | 0.075%        |\n| TPMT*1/*34    | 1                  | 0.075%        |\n| TPMT*2/*3A    | 1                  | 0.075%        |\n| TPMT*3A/*3A   | 1                  | 0.075%        |\n| TPMT*3C/*3C   | 1                  | 0.075%        |\n\n- The study included a total of 1334 patients with available TPMT genotype data.\n- The majority of patients (90.4%) were homozygous wild-type TPMT*1/*1.\n- The most common variant allele was TPMT*1/*3A, found in 7.4% of the patients.\n- Other variant alleles were present at much lower frequencies.\n\nThis table summarizes the distribution of TPMT genotypes among the study population, highlighting the predominance of the wild-type allele and the relative rarity of variant alleles.",
            "citations": [
                "*TPMT*TPMT genotype was available for 1334 patients (69% of patients entered onto ALL97); 1160 were white and 174 belonged to other ethnic groups (71 Asian (Indian sub\u2010continent), 44 mixed race, 20 black, 6 Oriental and 33 unknown or non\u2010Caucasian).",
                "1206 patients were homozygous wild\u2010type *TPMT*1/*1*TPMT*1/*1 and 128 patients had low activity variant alleles (99 *TPMT*1/*3A*TPMT*1/*3A; 17 *TPMT*1/*3C*TPMT*1/*3C; 4 *TPMT*1/*2*TPMT*1/*2; two children with the rare alleles *TPMT*1/*9*TPMT*1/*9,* TPMT*1/*21* TPMT*1/*21; three children with novel alleles *TPMT*1/*32, TPMT*1/*33, TPMT*1/*34*TPMT*1/*32, TPMT*1/*33, TPMT*1/*34; one compound heterozygote *TPMT*2/*3A*TPMT*2/*3A; one homozygous *TPMT*3A/*3A*TPMT*3A/*3A and one *TPMT*3C/*3C*TPMT*3C/*3C).",
                "## Table 4. Thiopurine dosage and myelosuppression by TPMT genotype"
            ]
        },
        "additional_resource_links": [
            "The study provides the following additional resources or links related to its design and execution:",
            "- [DOI link to the article](https://doi.org/10.1111/bjh.13240)",
            "- [PubMed Central (PMC) link to the article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737107/)",
            "- [PDF of the article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4737107/pdf/BJH-169-228.pdf)",
            "These resources provide access to the full text of the study and its supplementary materials."
        ]
    },
    "annotations": {
        "relationships": [
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes had significantly better 5-year event-free survival (EFS) than both TPMT wild-type (TPMT*1/*1) and TPMT*1/*3C heterozygotes. EFS for TPMT*1/*3A was 88%, compared to 80% for TPMT*1/*1 and 53% for TPMT*1/*3C.",
                "p_value": "TPMT*1/*3A vs TPMT*1/*1: P = 0.05; TPMT*1/*3A vs TPMT*1/*3C: P = 0.002",
                "citations": [
                    "Event\u2010free survival (EFS) for patients heterozygous for the more common TPMT*1/*3A variant allele (n = 99, 5\u2010year EFS 88%) was better than for both wild\u2010type TPMT*1/*1 (n = 1206, EFS 80%, P = 0\u00b705) and TPMT*1/*3C patients (n = 17, EFS 53%, P = 0\u00b7002); outcomes supported by a multivariate Cox regression analysis.",
                    "TPMT*1/*3A patients (EFS 88%, 95%CI 81\u201394%) fared significantly better than TPMT*1/*1 (EFS 80%, 95%CI 78\u201382%) patients (Fig 2).",
                    "In a multivariate Cox regression analysis, the worse survival for TPMT*1/*3C against TPMT*1/*3A (TPMT*1/*3C hazard ratio = 4\u00b75, 95% CI 1\u00b77\u201311\u00b78, P = 0\u00b7003) and for TPMT*1/*3C against TPMT*1/*1 and all other TPMT variant heterozygous genotypes (Table 5) retained significance in models for overall EFS that also included the covariates trial, age group, WBC at diagnosis and steroid randomization."
                ],
                "p_value_citations": [
                    "Event\u2010free survival (EFS) for patients heterozygous for the more common TPMT*1/*3A variant allele (n = 99, 5\u2010year EFS 88%) was better than for both wild\u2010type TPMT*1/*1 (n = 1206, EFS 80%, P = 0\u00b705) and TPMT*1/*3C patients (n = 17, EFS 53%, P = 0\u00b7002); outcomes supported by a multivariate Cox regression analysis."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3C (heterozygote)",
                "relationship_effect": "TPMT*1/*3C heterozygotes had significantly worse 5-year event-free survival (EFS) than both TPMT*1/*3A heterozygotes and TPMT*1/*1 wild-type. EFS for TPMT*1/*3C was 53%.",
                "p_value": "TPMT*1/*3C vs TPMT*1/*3A: P = 0.002; TPMT*1/*3C vs TPMT*1/*1: P = 0.03",
                "citations": [
                    "Heterozygous *TPMT*1/*3C*TPMT*1/*3C patients fared worse (5\u2010year EFS, 53%, 95%CI 29\u201377%) compared to the other heterozygous *TPMT*TPMT patients (*TPMT*1/*3A, *1/*2, *1/*21, *1/*9, *1/*32, *1/*33, *1/*34*TPMT*1/*3A, *1/*2, *1/*21, *1/*9, *1/*32, *1/*33, *1/*34; EFS 89%, 95%CI 83\u201395%, *P *P = 0\u00b7002) and homozygous *TPMT*1/*1*TPMT*1/*1 patients (EFS 80%%, 95%CI 78\u201382%, *P *P = 0\u00b703).",
                    "*TPMT*1/*3A*TPMT*1/*3A patients (EFS 88%, 95%CI 81\u201394%) fared significantly better than *TPMT*1/*1*TPMT*1/*1 (EFS 80%, 95%CI 78\u201382%) patients (Fig [2](#bjh13240-fig-0002)2).",
                    "In a multivariate Cox regression analysis, the worse survival for *TPMT*1/*3C*TPMT*1/*3C against *TPMT*1/*3A*TPMT*1/*3A (*TPMT*1/*3C*TPMT*1/*3C hazard ratio = 4\u00b75, 95% CI 1\u00b77\u201311\u00b78, *P *P = 0\u00b7003) and for *TPMT*1/*3C*TPMT*1/*3C against *TPMT*1/*1*TPMT*1/*1 and all other *TPMT*TPMT variant heterozygous genotypes (Table [5](#bjh13240-tbl-0005)5) retained significance in models for overall EFS that also included the covariates trial, age group, WBC at diagnosis and steroid randomization."
                ],
                "p_value_citations": [
                    "Heterozygous TPMT*1/*3C patients fared worse (5\u2010year EFS, 53%, 95%CI 29\u201377%) compared to the other heterozygous TPMT patients (TPMT*1/*3A, *1/*2, *1/*21, *1/*9, *1/*32, *1/*33, *1/*34; EFS 89%, 95%CI 83\u201395%, P = 0\u00b7002) and homozygous TPMT*1/*1 patients (EFS 80%%, 95%CI 78\u201382%, P = 0\u00b703)."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*1 (wild-type)",
                "relationship_effect": "TPMT*1/*1 wild-type patients had lower 5-year event-free survival (EFS) than TPMT*1/*3A heterozygotes (80% vs 88%).",
                "p_value": "P = 0.05",
                "citations": [
                    "Event\u2010free survival (EFS) for patients heterozygous for the more common TPMT*1/*3A variant allele (n = 99, 5\u2010year EFS 88%) was better than for both wild\u2010type TPMT*1/*1 (n = 1206, EFS 80%, P = 0\u00b705) and TPMT*1/*3C patients (n = 17, EFS 53%, P = 0\u00b7002); outcomes supported by a multivariate Cox regression analysis.",
                    "TPMT*1/*3A patients (EFS 88%, 95%CI 81\u201394%) fared significantly better than TPMT*1/*1 (EFS 80%, 95%CI 78\u201382%) patients (Fig 2).",
                    "In conclusion, TPMT*1/*3A heterozygotes had a better EFS than TPMT wild\u2010type patients."
                ],
                "p_value_citations": [
                    "Event\u2010free survival (EFS) for patients heterozygous for the more common TPMT*1/*3A variant allele (n = 99, 5\u2010year EFS 88%) was better than for both wild\u2010type TPMT*1/*1 (n = 1206, EFS 80%, P = 0\u00b705) and TPMT*1/*3C patients (n = 17, EFS 53%, P = 0\u00b7002); outcomes supported by a multivariate Cox regression analysis."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes tolerated a significantly lower average daily thiopurine dose than TPMT*1/*1 wild-type patients (70% vs 78% of protocol dose) and experienced more cytopenias.",
                "p_value": "P < 0.0002 (dose); P < 0.001 (time with dose withdrawn)",
                "citations": [
                    "Comparing the *TPMT*TPMT wild\u2010type (*TPMT*1/*1*TPMT*1/*1) patients with the *TPMT*TPMT wild\u2010type/variant allele heterozygotes, the former had a higher average dose than the latter (78% versus 70% respectively, *P *P < 0\u00b70002) and experienced less time with the dose withdrawn due to cytopenias (15\u00b75% vs. 20\u00b78% of time respectively, *P *P < 0\u00b7001).",
                    "The *TPMT*TPMT heterozygotes tolerated a significantly lower average daily thiopurine dose than the *TPMT*TPMT wild\u2010type patients and experienced more cytopenias.",
                    "## Table 4. Thiopurine dosage and myelosuppression by TPMT genotype"
                ],
                "p_value_citations": [
                    "Comparing the TPMT wild\u2010type (TPMT*1/*1) patients with the TPMT wild\u2010type/variant allele heterozygotes, the former had a higher average dose than the latter (78% versus 70% respectively, P < 0\u00b70002) and experienced less time with the dose withdrawn due to cytopenias (15\u00b75% vs. 20\u00b78% of time respectively, P < 0\u00b7001)."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes accumulated significantly higher thioguanine nucleotide (TGN) concentrations compared to TPMT*1/*1 wild-type patients (mercaptopurine-derived TGNs: 754 vs 360 pmol/8x10^8 red cells).",
                "p_value": "P < 0.0001",
                "citations": [
                    "For both genders and both thiopurines, TPMT heterozygous patients accumulated significantly higher TGN concentrations compared to the TPMT wild\u2010type cohort (Relling et al, 1999a; Lennard et al, 2013).",
                    "MP\u2010TGNs pmol | 360 (0\u20131216) | 754 (132\u20132228) | 394 (326 to 466), P < 0\u00b70001 |"
                ],
                "p_value_citations": [
                    "MP\u2010TGNs pmol | 360 (0\u20131216) | 754 (132\u20132228) | 394 (326 to 466), P < 0\u00b70001"
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes accumulated significantly lower methylmercaptopurine nucleotide (MeMPN) concentrations compared to TPMT*1/*1 wild-type patients (mercaptopurine-derived MeMPNs: 4078 vs 10702 pmol/8x10^8 red cells).",
                "p_value": "P < 0.0001",
                "citations": [
                    "MeMPN concentrations were also lower in *TPMT *1/*3C*TPMT *1/*3C patients; *TPMT *1/*3C*TPMT *1/*3C median MeMPN 2061 pmol/8 \u00d7 10^8^8 red cells (range 60 to 10746) and *TPMT *1/*3A*TPMT *1/*3A median MeMPN 4542 (range 84 to 38 386), median difference 2190 pmol (95% CI \u221254 to 5180), *P *P = 0\u00b706).",
                    "| MP\u2010MeMPNs pmol | 10702 (0\u2013141772) | 4078 (60\u201338386) | \u22125464 (\u22127278 to \u22123808), P < 0\u00b70001 |"
                ],
                "p_value_citations": [
                    "MP\u2010MeMPNs pmol | 10702 (0\u2013141772) | 4078 (60\u201338386) | \u22125464 (\u22127278 to \u22123808), P < 0\u00b70001"
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3C (heterozygote)",
                "relationship_effect": "TPMT*1/*3C heterozygotes accumulated significantly lower TGN concentrations than TPMT*1/*3A heterozygotes (median TGNs 608 vs 802 pmol/8x10^8 red cells).",
                "p_value": "P = 0.05",
                "citations": [
                    "Comparisons between *TPMT*TPMT heterozygotes were not possible with thioguanine (only four *TPMT*1/*3C*TPMT*1/*3C children), but within the mercaptopurine cohort *TPMT *1/*3C*TPMT *1/*3C children (*n *n = 12) had significantly lower TGN concentrations than *TPMT *1/*3A*TPMT *1/*3A children (*n *n = 53) despite having similar drug dosages and TPMT activities (Lennard *et al*et al, [2013](#bjh13240-bib-0015)2013); *TPMT *1/*3C*TPMT *1/*3C median TGNs 608 pmol/8 \u00d7 10^8^8 red cells (range 288 to 910) and *TPMT *1/*3A*TPMT *1/*3A median TGNs 802 (range 132 to 2228), median difference 192 pmol (95% confidence interval [CI] 10 to 425), *P *P = 0\u00b705).",
                    "Despite similar mercaptopurine dosages and TPMT activities, the *TPMT*1/*3C*TPMT*1/*3C patients accumulated significantly less TGNs and lower MeMPN concentrations than *TPMT*1/*3A*TPMT*1/*3A patients; this could indicate an increased frequency of non\u2010adherence and suboptimal metabolite exposure in the *TPMT*1/*3C*TPMT*1/*3C cohort.",
                    "## Table 1: Thiopurine methyltransferase genotype and metabolite formation"
                ],
                "p_value_citations": [
                    "within the mercaptopurine cohort TPMT*1/*3C children (n = 12) had significantly lower TGN concentrations than TPMT*1/*3A children (n = 53) despite having similar drug dosages and TPMT activities; TPMT*1/*3C median TGNs 608 pmol/8 \u00d7 10^8 red cells (range 288 to 910) and TPMT*1/*3A median TGNs 802 (range 132 to 2228), median difference 192 pmol (95% confidence interval [CI] 10 to 425), P = 0\u00b705."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3C (heterozygote)",
                "relationship_effect": "TPMT*1/*3C heterozygotes accumulated lower MeMPN concentrations than TPMT*1/*3A heterozygotes (median MeMPN 2061 vs 4542 pmol/8x10^8 red cells).",
                "p_value": "P = 0.06 (not significant)",
                "citations": [
                    "MeMPN concentrations were also lower in *TPMT *1/*3C*TPMT *1/*3C patients; *TPMT *1/*3C*TPMT *1/*3C median MeMPN 2061 pmol/8 \u00d7 10^8^8 red cells (range 60 to 10746) and *TPMT *1/*3A*TPMT *1/*3A median MeMPN 4542 (range 84 to 38 386), median difference 2190 pmol (95% CI \u221254 to 5180), *P *P = 0\u00b706).",
                    "Despite similar mercaptopurine dosages and TPMT activities, the *TPMT*1/*3C*TPMT*1/*3C patients accumulated significantly less TGNs and lower MeMPN concentrations than *TPMT*1/*3A*TPMT*1/*3A patients; this could indicate an increased frequency of non\u2010adherence and suboptimal metabolite exposure in the *TPMT*1/*3C*TPMT*1/*3C cohort.",
                    "## Table 1. Thiopurine methyltransferase genotype and metabolite formation"
                ],
                "p_value_citations": [
                    "MeMPN concentrations were also lower in TPMT*1/*3C patients; TPMT*1/*3C median MeMPN 2061 pmol/8 \u00d7 10^8 red cells (range 60 to 10746) and TPMT*1/*3A median MeMPN 4542 (range 84 to 38 386), median difference 2190 pmol (95% CI \u221254 to 5180), P = 0\u00b706."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes experienced more cytopenias and required dose adjustments below target levels significantly more often than TPMT*1/*1 wild-type patients.",
                "p_value": "P < 0.001 (time with dose withdrawn); P = 0.0002 (average dose)",
                "citations": [
                    "Comparing the *TPMT*TPMT wild\u2010type (*TPMT*1/*1*TPMT*1/*1) patients with the *TPMT*TPMT wild\u2010type/variant allele heterozygotes, the former had a higher average dose than the latter (78% versus 70% respectively, *P *P < 0\u00b70002) and experienced less time with the dose withdrawn due to cytopenias (15\u00b75% vs. 20\u00b78% of time respectively, *P *P < 0\u00b7001).",
                    "The *TPMT*TPMT heterozygotes tolerated a significantly lower average daily thiopurine dose than the *TPMT*TPMT wild\u2010type patients and experienced more cytopenias.",
                    "## Table 4. Thiopurine dosage and myelosuppression by TPMT genotype"
                ],
                "p_value_citations": [
                    "Comparing the TPMT wild\u2010type (TPMT*1/*1) patients with the TPMT wild\u2010type/variant allele heterozygotes, the former had a higher average dose than the latter (78% versus 70% respectively, P < 0\u00b70002) and experienced less time with the dose withdrawn due to cytopenias (15\u00b75% vs. 20\u00b78% of time respectively, P < 0\u00b7001)."
                ]
            },
            {
                "gene": "TPMT",
                "polymorphism": "TPMT*1/*3A (heterozygote)",
                "relationship_effect": "TPMT*1/*3A heterozygotes had a higher frequency of cytopenias and higher TGN concentrations, but neither the reference TGN concentration nor the frequency of cytopenias was directly associated with EFS.",
                "p_value": "Not significant for EFS",
                "citations": [
                    "The TPMT heterozygotes tolerated a significantly lower average daily thiopurine dose than the TPMT wild\u2010type patients and experienced more cytopenias.",
                    "For both genders and both thiopurines, TPMT heterozygous patients accumulated significantly higher TGN concentrations compared to the TPMT wild\u2010type cohort (Relling et al, 1999a; Lennard et al, 2013).",
                    "TPMT *1/*3A patients had a better EFS than TPMT *1/*1 patients, the former also experienced more cytopenias and accumulated higher TGN concentrations than the latter. However, neither the reference TGN concentration nor the frequency of cytopenias throughout thiopurine chemotherapy were directly associated with EFS."
                ],
                "p_value_citations": [
                    "However, neither the reference TGN concentration nor the frequency of cytopenias throughout thiopurine chemotherapy were directly associated with EFS."
                ]
            }
        ]
    }
}